ReviewClinical transplantation and research2025
Deceased organ donation: laboratory testing and histocompatibility assessment in Korea.
Review in Clinical transplantation and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- IgG Subclass Profiles of HLA Antibodies Enhance Prediction of C1q-Binding in Kidney Transplant Recipients.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histocompatibility testing is essential for ensuring both safety and fairness in deceased donor organ transplantation. In Korea, such testing is strictly regulated under the Organ Transplant Act and centralized within organ procurement organization laboratories. Standardized evaluations include ABO blood typing, infectious disease screening, human leukocyte antigen (HLA) typing, and crossmatching. Current allocation policies rely on low-resolution HLA typing and mandatory complement-dependent cytotoxicity crossmatch, with limited accommodations for highly sensitized patients; however, these measures remain inadequate to resolve prolonged waiting times and inequities. The integration of calculated panel-reactive antibody and virtual crossmatching provides opportunities to improve allocation fairness, reduce cold ischemic time, and minimize unnecessary crossmatches. This review outlines the Korean system of histocompatibility testing in deceased donor transplantation, highlights current challenges, and explores potential strategies for future improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.